Pharmaceuticals

Enliven Therapeutics

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

LifeSci Capital Maintains Buy Rating on Enliven Therapeutics

Enliven Therapeutics released FY2025 Annual Earnings on March 3 (EST), actual revenue USD 0 (forecast USD 10K), actual EPS USD -1.8299 (forecast USD -1.7328)

Enliven Therapeutics released FY2025 Q4 earnings on March 3 (EST), actual revenue USD 0 (forecast USD 10 K), actual EPS USD -0.4768 (forecast USD -0.3857)

Enliven Therapeutics' Leukemia Candidate ELVN-001 Shows Positive Clinical Trial Results

Enliven Therapeutics Inc. COO Reports Disposal of Common Stock

Enliven Therapeutics Reports Positive Phase 1b Results for Chronic Myeloid Leukemia Drug ELVN-001

Enliven Therapeutics, Inc. Receives Significant Funding

Candriam S.C.A. Invests in Enliven Therapeutics, Inc.

H.C. Wainwright Reiterates Buy Rating on Enliven Therapeutics

Enliven Therapeutics released FY2025 9 Months earnings on November 12 (EST), actual revenue USD 0, actual EPS USD -1.381

Enliven Therapeutics released FY2025 Q3 earnings on November 12, 2025 (EST), with actual revenue USD 0 (forecast USD 0) and actual EPS USD 0 (forecast USD -0.4362)

Syed Recommends Enliven Therapeutics Stock with a Buy Rating

Enliven Therapeutics to Present ELVN-001 Preliminary Clinical Data at ASH Annual Meeting

Analyst Roy Covers Healthcare Stocks

Enliven Therapeutics released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -1.0547

Enliven Therapeutics released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.49 (forecast USD -0.5337)

Enliven Therapeutics Inc. CFO Reports Common Stock Disposition

Enliven Therapeutics COO Disposes of Common Stock

Enliven Therapeutics stock price rises, analysts upgrade rating

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ELVN

Boris Peaker of JonesTrading has reiterated a Buy rating on ELVN-001, maintaining a $45 price target due to strong clinical data and strategic positioning. The drug shows promising molecular response rates and tolerability in late-line CML patients. Peaker highlights ELVN-001's unique mechanism and efficacy compared to competitors, alongside the company's solid cash position. Guggenheim also initiated coverage with a Buy rating and a $80 price target. Peaker has a 20.3% average return and a 45.78% success rate on his stock recommendations.

Tip Ranks

Relay Therapeutics

Nuvation Bio

NUVATION BIO INC C/WTS 10/02/2026 (TO PUR COM)

Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

StockTitan

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

ARKG

Needham analyst Boris Peaker has reiterated a Buy rating on Enliven's ELVN stock, citing strong efficacy of ELVN-001 in chronic myeloid leukemia (CML) compared to existing therapies. He highlights significant early Phase 1 data and upcoming catalysts, including additional Phase 1 data in mid-2026 and the pivotal Phase 3 ENABLE-2 trial starting in late 2026. Peaker views Enliven as a strategic asset, especially after Merck's acquisition of a competitor, positioning it well for potential takeover opportunities. Clear Street also maintains a Buy rating with a $55 price target.

iShares US Pharma

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

iShares Global Healthcare

iShares Biotechnology ETF

SPDR S&P Biotech

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

VG Health

ALPS Medical Breakthrough

Merck

Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway

Earnings Watch

Enliven Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Enliven Therapeutics, Inc. (Nasdaq: ELVN) reported its first quarter financial results for 2026, highlighting a strong cash position of $452 million, expected to last until mid-2029. The company is preparing to initiate the Phase 3 ENABLE-2 trial for ELVN-001 in the second half of 2026, following positive Phase 1b data. R&D expenses decreased to $20.7 million, while G&A expenses rose to $7.1 million, resulting in a net loss of $23.6 million. Enliven aims to address unmet needs in chronic myeloid leukemia with its innovative therapies.

prnewswire

16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics (NASDAQ:ELVN) is set to release its Q1 2026 earnings on May 13, with analysts predicting a loss of $0.44 per share. The company recently reported a loss of $0.48 per share for the previous quarter, missing estimates. The stock is currently priced at $41.58, with a market cap of $2.53 billion. Analyst ratings vary, with five analysts rating it as a "Buy" and one as a "Sell." Insider trading activity includes recent sales by the CFO and a director. Institutional investors have also adjusted their stakes in the company.

Market Beat

Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday

Enliven Therapeutics(ELVN.US)

Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML | ELVN Stock News

Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway

Enliven Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday